REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
REGENXBIO reported Q1 2026 revenue of $6.4 million, a significant 92.8% decrease from the $89.0 million reported in Q1 2025. The decrease was primarily due to a $70.0 million upfront license recognized under the collaboration with Nippon Shinyaku in Q1 2025 and a $12.2 million decrease in ZOLGENSMA royalty revenues. The company announced positive topline results from the pivotal Phase III AFFINITY DUCHENNE trial of RGX-202, achieving the primary endpoint with high statistical significance. 93% of patients achieved microdystrophin expression above 10% (p<0.0001), and there was a statistically significant correlation between microdystrophin expression and functional improvement (NSAA, n=9).
Key figures
- Eps Beat
- 0
- Revenue
- 6393000
- Guidance
- Cash, cash equivalents and marketable securities of $150.5 million as of March 31, 2026 to fund operations into early 2027
- Revenue Yoy
- -92.8%
- Net loss
- 90051000
- G a expenses
- 21306000
- R d expenses
- 57339000
- Cash position
- 150500000
- Functional improvement
- Statistically significant correlation between RGX-202 microdystrophin expression level and functional improvement (NSAA, n=9)
- Microdystrophin expression
- 93% of patients achieved RGX-202 microdystrophin expression above 10% (p<0.0001)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.